The Technical Analyst
Codiak BioSciences, Inc. [CDAK]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Codiak BioSciences, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0570
America/New_York / 4 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2.83 mill |
| EPS: | -0.460 |
| P/E: | -0.120 |
| Earnings Date: | Aug 02, 2023 |
| SharesOutstanding: | 49.63 mill |
| Avg Daily Volume: | 0 mill |
| RATING 2023-05-23 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.120 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.02x |
| Company: PE -0.120 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ -0.0010 - 0.0410 ( +/- 105.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-30 | Howze Yalonda | Sell | 1 628 | Common Stock |
| 2023-03-29 | Sathyanarayanan Sriram | Sell | 11 762 | Common Stock |
| 2023-03-28 | Konstantinov Konstantin | Sell | 7 432 | Common Stock |
| 2023-03-28 | Konstantinov Konstantin | Sell | 1 932 | Common Stock |
| 2023-03-28 | Bain Linda | Sell | 13 412 | Common Stock |
| INSIDER POWER |
|---|
| 93.09 |
| Last 100 transactions |
| Buy: 14 044 661 | Sell: 316 076 |
Forecast:
01:40 - $-0.0530
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.0570 (0.00% ) |
| Volume | 14.21 mill |
| Avg. Vol. | 0 mill |
| % of Avg. Vol | 0 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CDAK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CDAK
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2022-10-05 08:00:00 - Press Release
Codiak To Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
– data to be presented at the society for immunotherapy of cancer (sitc) annual meeting –
2022-01-06 09:00:00 - Press Release
Codiak Biosciences To Present At The H.c. Wainwright Virtual Bioconnect 2022 Conference
Cambridge, mass., jan. 06, 2022 (globe newswire) -- codiak biosciences, inc. (nasdaq: cdak), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that douglas e. williams, ph.d., president and ceo, and linda c. bain, cfo, will participate in the h.c. wainwright virtual bioconnect 2022 conference, which is taking place from monday, january 10 to thursday, january 13.
2021-12-01 16:05:00 - Press Release
Codiak Biosciences To Present At The 4th Annual Evercore Isi Healthconx Conference
Cambridge, mass., dec. 01, 2021 (globe newswire) -- codiak biosciences, inc. (nasdaq: cdak), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that douglas e. williams, ph.d., president and ceo, will participate in a virtual fireside chat at the 4th annual evercore isi healthconx conference. details are as follows:
2021-10-01 08:00:00 - Press Release
Codiak To Present Preclinical Data Demonstrating New Potential Therapeutic Applications Of Engineered Exosomes At The Society For Immunotherapy Of Cancer (sitc) Annual Meeting
Cambridge, mass., oct. 01, 2021 (globe newswire) -- codiak biosciences, inc. (nasdaq: cdak), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that three posters featuring preclinical data from its engex™ platform programs will be presented during the 36th annual meeting of the society for immunotherapy of cancer (sitc 2021), which is being held virtually and in person in washington, d.c. from november 10-14, 2021.
2021-08-18 08:30:00 - Press Release
Codiak Biosciences Appoints Lini Pandite, Mbchb, Mba To Board Of Directors
Cambridge, mass., aug. 18, 2021 (globe newswire) -- codiak biosciences, inc. (nasdaq: cdak), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has appointed lini pandite, mbchb, mba to its board of directors. as a board-certified oncologist and current chief medical officer at shattuck labs, dr. pandite brings extensive expertise in oncology drug development and clinical application, diversifying the breadth of expertise represented on the board.
Latest News
2023-03-27 12:17:56 - InvestorPlace
Why Is Codiak BioSciences (CDAK) Stock Down 52% Today?
Codiak BioSciences (NASDAQ: CDAK ) stock is falling hard on Monday after the company announced plans for an asset sale through a Chapter 11 bankruptcy. According to a press release, Codiak BioSciences started the marketing process before entering into Chapter 11.
2023-03-27 07:26:00 - Market Watch
Codiak BioSciences files for bankruptcy, looks to sell off assets
Codiak BioSciences Inc. CDAK, -4.56% said Monday that it has field for bankruptcy, and it looking to selloff of its assets to maximize the company's value. “The Board and management team have thoroughly assessed all of our strategic options and believe that this structured process represents the best possible solution for Codiak, taking into account our financial needs and the stage of our clinical and research programs,” the Massachusetts-based biopharmaceutical company said in a statement.
2022-11-03 18:48:16 - Zacks Investment Research
Codiak BioSciences, Inc. (CDAK) Reports Q3 Loss, Lags Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 6.10% and 70.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-10-05 08:00:00 - GlobeNewsWire
Codiak to Present New Preclinical Data Demonstrating Potent Monotherapy Activity of Two Engineered Exosome Intravenous Candidates Targeting Macrophages
– Data to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting –
2022-08-04 18:48:32 - Zacks Investment Research
Codiak BioSciences, Inc. (CDAK) Reports Q2 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 61.54% and 701.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-06-30 09:52:02 - Benzinga
Codiak BioSciences' Engineered Exosome Candidates Show Early Antitumor Activity
Codiak BioSciences Inc (NASDAQ: CDAK) announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials. In an open-label Phase 1 trial, exoIL-12 demonstrated a differentiating favorable safety.
2022-05-05 19:34:24 - Zacks Investment Research
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-03-29 11:17:14 - Zacks Investment Research
Codiak BioSciences, Inc. (CDAK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Codiak BioSciences, Inc. (CDAK), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
2022-03-12 06:10:37 - 24/7 Wall Street
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 700% Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
2022-03-10 18:48:25 - Zacks Investment Research
Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?